en
Scientific article
Review
English

MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective

Published inAlimentary Pharmacology and Therapeutics, vol. 53, no. 10, p. 1080-1089
Publication date2021
Abstract

The World Health Organization (WHO) set a goal to eliminate hepatitis C (HCV) infection globally by 2030, with specific targets to reduce new viral hepatitis infections by 80% and reduce related deaths by 65%. However, an overlooked aspect that may hinder these efforts is the impact other liver diseases could have by continuing to drive liver disease progression and offset the beneficial impact of DAAs on end-stage liver disease and hepatocellular carcinoma (HCC). In particular, the decrease in HCV prevalence has been countered by a marked increase in the prevalence of metabolic-associated fatty liver disease (MAFLD).

Keywords
  • Antiviral Agents/therapeutic use
  • Carcinoma
  • Hepatocellular/drug therapy
  • Hepatitis C/drug therapy/epidemiology
  • Hepatitis C
  • Chronic/drug therapy/epidemiology
  • Humans
  • Internationality
  • Liver Neoplasms/drug therapy
  • Quality of Life
Citation (ISO format)
FOUAD, Yasser et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. In: Alimentary Pharmacology and Therapeutics, 2021, vol. 53, n° 10, p. 1080–1089. doi: 10.1111/apt.16346
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0269-2813
160views
0downloads

Technical informations

Creation06/17/2021 3:35:00 PM
First validation06/17/2021 3:35:00 PM
Update time03/16/2023 12:49:14 AM
Status update03/16/2023 12:49:13 AM
Last indexation01/17/2024 1:35:12 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack